LETROZOLE IN THE TREATMENTOF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER

are hormone sensitive, and hormonetherapy is effective for many of these patients. The aim of this study is to evaluate the efficacy and safety of treatment with Letrozole in postmenopausal women with advanced or metastatic breast cancer. Methods: Thirty two postmenopausal women with histologically or cytologically proven breast cancer who presented with either locally advanced or had metastatic breast cancer, entered the study. Tumors were required to be estrogen or progesterone receptor positive. Therapy consists of Letrozole 1 mg daily per os. Results: Thirty two patients were treated in Pleven Medical University-Department of chemotherapy. Three complete responses and seven partial responses were obtained. The main grade toxicity included rush and hot flushes. Conclusions: Letrozole was effective in patients with advanced or metastatic breast cancer with 38.2 % response rate and mild to moderate toxicity